Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to veligrotug ('veli'), the company's lead anti-insulin-like growth factor-1 receptor (IGF-1R) drug candidate for the treatment of TED.
Breakthrough Therapy Designation is reserved for drug candidates intended to treat serious or life-threatening conditions that address an unmet need where clinical evidence has indicated they may demonstrate substantial improvement on a clinically significant endpoint over existing therapies.
'The FDA's decision to grant veli Breakthrough Therapy Designation underscores that veli may offer substantial improvement over existing therapies, and we believe it reinforces veli's potential to be a differentiated, treatment-of-choice for patients living with TED,' said Steve Mahoney, Viridian's President and CEO. 'Veli is the only therapy that has demonstrated statistically significant and clinically meaningful improvement and resolution of diplopia in both active and chronic TED. Veli also showed a rapid onset of treatment effect, including an improvement in proptosis response in as few as three weeks after just one infusion. We believe veli will be an important potential new treatment option for patients living with TED, including whose disease is unaddressed by existing therapies. We continue to execute on our planned BLA submission in the second half of 2025 and are excited that this designation supports eligibility for Priority Review as we prepare for our planned U.S. commercial launch in 2026.'
THRIVE and THRIVE-2, phase 3 clinical trials in active and chronic TED respectively, comprise the largest pivotal program to date in TED. In both clinical trials, veligrotug met all of its primary and secondary endpoints and was generally well-tolerated. THRIVE-2 was the first global phase 3 clinical trial to demonstrate a statistically significant diplopia response and resolution in chronic TED patients.
About Veligrotug
Veligrotug is an intravenously (IV) delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody in phase 3 development for thyroid eye disease, with the potential to be the IV treatment-of-choice for active and chronic TED patients. IGF-1R is a clinically and commercially validated target for thyroid eye disease (TED) with U.S. revenues of approximately $2 billion in 2024. Veligrotug has the potential to improve patient experience with a differentiated dosing regimen that features a shorter infusion time and fewer infusions compared to the currently approved and marketed IGF-1R inhibitor.
In its pivotal phase 3 clinical trials, THRIVE and THRIVE-2, veligrotug met all of its primary and secondary endpoints. Veligrotug demonstrated a rapid onset of treatment effect and statistically significant and clinically meaningful reduction and resolution of diplopia in both clinical trials. THRIVE-2 was the first demonstration in a global phase 3 clinical trial of a statistically significant diplopia response and resolution in chronic TED patients. Veligrotug was generally well tolerated.
Viridian believes that the differentiated Veligrotug has the potential to establish a strong position in the TED commercial market, if approved, and may help facilitate the introduction of VRDN-003, its potential best-in-class subcutaneous IGF-1R antibody for TED.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, 'anticipate,' 'believe,' 'become,' 'continue,' 'could,' 'design,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'on track,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or other similar terms or expressions that concern our expectations, plans and intentions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, and assumptions. Forward-looking statements include, without limitation, statements regarding: clinical development and anticipated commercialization of Viridian's product candidates, including veligrotug (formerly VRDN-001) and VRDN-003; the impact of Breakthrough Therapy Designation, including eligibility for Priority Review, or any other FDA designations; regulatory interactions and anticipated timing of regulatory submissions, including the anticipated BLA submission for veligrotug in the second half of 2025; the potential utility, efficacy, potency, safety, clinical benefits, clinical response, convenience, and number of indications of veligrotug and VRDN-003; veligrotug's potential to be a differentiated, IV treatment-of-choice for active and chronic TED or an important potential new treatment option; potential market sizes and market opportunities, including for Viridian's product candidates; Viridian's product candidates potentially being best-in-class; whether veligrotug will serve an unmet need; whether veligrotug may offer substantial improvement over existing therapies; and Viridian's expectations regarding the potential commercialization of veligrotug and VRDN-003, if approved, including the potential U.S. launch of veligrotug in 2026.
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: potential utility, efficacy, potency, safety, clinical benefits, clinical response, and convenience of Viridian's product candidates; that results or data from completed or ongoing clinical trials may not be representative of the results of ongoing or future clinical trials; that preliminary data may not be representative of final data; expectations and changes regarding the timing for regulatory filings; regulatory interactions; uncertainty and potential delays related to clinical drug development; the timing of and our ability to obtain and maintain regulatory approvals for our therapeutic candidates; competition from other therapies or products; estimates of market size; our future operating results and financial performance; Viridian's intellectual property position; that our product candidates may not be commercially successful, if approved; and other risks described from time to time in the 'Risk Factors' section of our filings with the Securities and Exchange Commission (SEC), including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statement speaks only as of the date on which it was made. Neither the company, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date hereof.
Source: Viridian Therapeutics, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
2 hours ago
- Chicago Tribune
Lake County nursing home won't sign union contract as state and local officials raise staffing concerns
Thrive of Lake County and Ignite Medical Resorts is facing criticism from local and state officials over its refusal to sign a previously negotiated union contract due to the included staffing requirements. Over 20 local officials, including two state senators, five state representatives and numerous members of the Lake County Board signed a letter urging the company to honor the contract and raised concerns over its staffing ratios. The nursing home was formerly known as Winchester House and located along Milwaukee Avenue when it was owned by Lake County. In 2015, it was sold to Thrive, and in 2020 was moved to its current location in Mundelein. In 2022, Thrive partnered with Ignite to manage the three Thrive locations in Illinois. The letter calls for the company to honor the collective bargaining agreement negotiated with AFSCME Local 2452 last year. As a formerly county-run nursing home, the company has a 'special responsibility to make resident care a top priority,' it said. Officials threw their weight behind the employees, arguing they were advocating for both themselves and the facility's residents. One of the union's main priorities is maintaining the contract's safe-staffing ratios, the letter said, and Thrive management had previously agreed to the contract, with union employees voting 'overwhelmingly to ratify it.' But Ignite's upper management did 'an about-face,' refusing to sign the contract, 'supposedly because of the inclusion of the safe-staffing provisions,' the letter said. This refusal is against the law according to the letter, and was 'especially concerning' given the company's 'demonstrated track record' of 'lower staffing, worse care and higher patient-mortality rates among nursing homes with private equity and real estate investment trust investors, like Thrive and Ignite.' The officials said they 'strongly object to this flagrant violation of the integrity of the collective bargaining process. We cannot stand idly by when it seems all too possible that corners are being cut to increase corporate profits while diminishing quality of care.' Robert Simandl, representing Thrive, said the company had 'met its legal obligations' to the union, and described the situation as an 'impasse in negotiations.' 'When there is not a meeting of the minds on all of the terms for a contract, it can become a reality,' Simandl said. Ignite was 'always' looking out for 'what is best for our residents — that is our charge,' Simandl said. Illinois staffing rules give long-term care provider employers 'flexibility to meet the needs of the residents,' he said. 'Adjusting staffing based on acuity of the resident is an absolute requirement for making sure the resident receives the best care for their situation,' Simandl said. 'Static staffing has been rejected under the State guidelines as our legislators recognize the need for facilities to be nimble.' According to Thrive is rated below average for health inspections, quality measures and staffing, and it has faced two federal fines in the last three years. Its total number of nurse staff hours per resident per day, 2 hours and 40 minutes, is more than an hour below the national average according to the website. According to Simandl, Thrive has increased its staffing in the last year, and they 'closely monitor the needs of our residents and will continue to meet the staffing requirements of law.' 'We have good people who take their responsibilities very seriously. This includes not only the represented staff but also the administrative people at the facility,' he said. 'We will continue to fulfill our legal obligations to our employees, the State, and our residents,' Simandl said. Maribel Novelo is a certified nurse assistant at Thrive of Lake County and has worked in the industry since she was 18. She said she loves her job and the connection she builds with the people she cares for. 'They become your family,' Novelo said. 'They become more like your grandma. You see your mom in them.' She described the powerful feeling of seeing so many local officials standing by the workers. 'I felt so good, I'm glad someone is on our side,' Novelo said. 'I really admire them now. I don't feel scared, I don't feel lonely, because I see that they're going to be there working with me.'
Los Angeles Times
4 hours ago
- Los Angeles Times
Early-Stage Technology Disruptions and Trends Set to Define the Future of Business Systems
Researchers point to technologies addressing GenAI-enabled code architecture, disinformation security and surface asset management as the most likely to be widely adopted by businesses by 2030, while leaders find themselves reassessing cloud usage and not overlooking the ever-growing need for effective cybersecurity solutions Through its research and surveys of C-suiters, Gartner, Inc. has identified the most likely emerging technology disruptions that will impact businesses and define the future of business systems. Technology leaders are clearly prioritizing these over the next five years, as they present competitive opportunities in the near term and will eventually grow to become standard throughout businesses. 'Technology leaders must take action now to gain a first-mover advantage with these technologies,' said Bill Ray, distinguished VP analyst at Gartner. 'Innovative advancements like generative AI-enabled code architecture, disinformation security and Earth intelligence will provide the differentiation needed to help enterprises pull ahead of the pack in terms of data and product offerings.' Each disruptor is significant in its own right, but in combination, they start to define broader emerging solutions to new business practices. For example, advancing GenAI technologies will spawn new solutions around Earth intelligence and business simulation, spur the expansive growth of domainspecific language models and lead to higher functioning tools. GenAI solutions systems using free-form text and multimedia inputs/outputs will displace the conventional form-oriented sequential UI in established enterprise applications and enable new user scenarios. 'To remain competitive, traditional enterprise application software vendors will need to refactor applications to serve composable GenAI solutions that are invoked on demand via textual and multimodal prompts,' said Ray Valdes, VP analyst at Gartner. Because of this, Gartner predicts that by 2029, more than 50% of user interactions linked to enterprise business processes will leverage large language models to bypass the UI layer in traditional enterprise applications, up from less than 5% today. Disinformation security is an emerging discipline focused on threats from outside the corporate-controlled network. It includes a suite of technologies, such as deepfake detection, impersonation prevention and reputation protection, which can address disinformation to help enterprises discern trust, protect their brand and secure their online presence. Gartner predicts that by 2030, at least half of enterprises will have adopted products or services to address disinformation security, up from less than 5% in 2024. 'Disinformation attacks use external infrastructure, like social media, and originate from areas with limited legal oversight,' said Alfredo Ramirez IV, senior director analyst at Gartner. 'Tech leaders must add 'disinformation-proofing' to products by using AI/machine learning for content verification and data provenance tracking to help users discern the truth.' Gartner predicts that by 2028, 80% of major Earth surface assets globally will be monitored by active satellites. Earth intelligence tech uses AI to analyze satellite, aerial and ground data to monitor Earth's assets and activities, providing insights for decision-making. 'That doesn't mean maps and charts. Earth intelligence is delivering numbers on global nickel production, theme park revenue and the health of wheat crops, to name just a few,' said Ray. Given the breadth of applications, Earth intelligence is applicable to all industries and enterprises. Defense has been the first adopter, but improvements in the quality of data and analysis techniques have rapidly expanded the use cases. The Earth intelligence market is now divided between those who capture the data, those who interpret and analyze it and those who generate industry-specific insights. 'Earth intelligence applies to every business,' said Ray. 'Enterprises can gain an early advantage by creatively and strategically applying Earth intelligence to significantly enhance specific functionalities of existing systems or to compete via new net capabilities.' In a separate research report, Gartner has also announced the top trends shaping the future of cloud adoption over the next four years. These include cloud dissatisfaction, AI/machine learning (ML), multicloud, sustainability, digital sovereignty and industry solutions. Joe Rogus, director, advisory at Gartner, said, 'These trends are accelerating the shift in how cloud is transforming from a technology enabler to a business disruptor and necessity for most organizations. Over the next few years, cloud will continue to unlock new business models, competitive advantages and ways of achieving business missions.' Cloud adoption continues to grow, but not all implementations succeed. Gartner predicts 25% of organizations will have experienced significant dissatisfaction with their cloud adoption by 2028, due to unrealistic expectations, suboptimal implementation and/or uncontrolled costs. To remain competitive, enterprises need a clear cloud strategy and effective execution. Gartner research indicates that those who have successfully addressed upfront strategic focus by 2029 will find their cloud dissatisfaction will decrease. Gartner also predicts 50% of cloud computing resources will be devoted to AI workloads by 2029, up from less than 10% today. 'This all points to a fivefold increase in AI-related cloud workloads by 2029,' said Rogus. 'Now is the time for organizations to assess whether their data centers and cloud strategies are ready to handle this surge in AI and ML demand. In many cases, they might need to bring AI to where the data is to support this growth.' Many organizations that have adopted multicloud architecture find connecting to and between providers a challenge. This lack of interoperability between environments can slow cloud adoption, with Gartner predicting more than 50% of organizations will not get the expected results from their multicloud implementations by 2029. Gartner recommends identifying specific use cases and planning for distributed apps and data in the organization that could benefit from a cross-cloud deployment model. This enables workloads to operate collaboratively across different cloud platforms, as well as different onpremises and colocation facilities. AI adoption, tightening privacy regulations and geopolitical tensions are also driving demand for sovereign cloud services. Organizations will be increasingly required to protect data, infrastructure and critical workloads from control by external jurisdictions and foreign government access. Gartner predicts over 50% of multinational organizations will have digital sovereign strategies by 2029, up from less than 10% today. 'As organizations proactively align their cloud strategies to address digital sovereignty requirements, there are already a wide range of offerings that will support them,' said Rogus. 'However, it's important they understand exactly what their requirements are, so they can select the right mix of solutions to safeguard their data and operational integrity.' With all the talk of businesses onboarding GenAI and other emerging technology solutions, it's easy to overlook cybersecurity tools. CEOs, however, are not forgetting to lock the proverbial door. Gartner's research has shown that a whopping 85% of CEOs surveyed say that cybersecurity is critical for business growth moving forward. In a survey of 456 CEOs and other senior business executives, 61% of CEOs are concerned about cybersecurity threats, driven in large part by AI's growing role in commercial activity and the political debates about the sourcing and use of advanced technologies. As risk thresholds shift, they view cybersecurity as a key driver. 'Cybersecurity is no longer just about protection; it's a critical driver for business growth,' said David Furlonger, distinguished vice president analyst and Gartner fellow. 'With 85% of CEOs recognizing its importance, security leaders have a unique opportunity to demonstrate the value of cybersecurity investments not only in safeguarding assets but also in enabling strategic business objectives.' 'Effective communication is key,' said Furlonger. 'CEOs should highlight the role of security leaders in both protecting the business and enhancing cybersecurity to drive growth. This involves, for example, assessing risks in foreign markets and intellectual property protection. Security leaders are positioned to significantly influence value generation, and they should communicate how cybersecurity aids enterprise growth.' With regulatory changes and cybersecurity threats challenging competitiveness, CEOs said they see a direct linkage between cybersecurity capabilities and enterprise growth. Meanwhile, C-suiters' comfort level with AI is far from established at this point. Only 44% of CIOs are deemed by their CEOs to be 'AI-savvy' according to the Gartner data. The survey revealed that 77% of CEOs believe that AI is indeed ushering in a new business era, yet they feel their organization's leading technology experts lack the knowledge and capabilities to support, drive or accelerate business outcomes in this evolving landscape. 'We have never seen such a disproportionate gap in CEOs' impressions about technological disruption,' said Furlonger. 'AI is not just an incremental change from digital business. AI is a step change in how business and society work. A significant implication is that if savviness across the C-suite is not rapidly improved, competitiveness will suffer and corporate survival will be at stake.' CEOs perceive even the CIO, chief information security officer (CISO) and chief data officer (CDO) as lacking AI savviness. CEOs highlighted that the top two limiting factors impacting AI's deployment and use are the inability to hire adequate numbers of skilled people and an inability to calculate value or outcomes. 'CEOs have shifted their view of AI from just a tool to a transformative way of working,' said Jennifer Carter, principal analyst at Gartner. 'This change has highlighted the importance of upskilling. As leaders recognize AI's potential and its impact on their organizations, they understand that success isn't just about hiring new talent. Instead, it's about equipping their current employees with the skills needed to seamlessly incorporate AI into everyday tasks.'
Miami Herald
4 hours ago
- Miami Herald
It sounds sick, but Iran hostilities may be good for stocks
So, President Trump ordered B-2 bombers to drop bunker-busting bombs on three Iranian nuclear facilities late Saturday. He pronounced the result "a spectacular success," with Iran's nuclear enrichment facilities "completely and totally obliterated." There will be lots of media coverage Sunday and beyond on whether the operation worked and whether the United States will be dragged into a third war in the Middle East since 1991. Don't miss the move: Subscribe to TheStreet's free daily newsletter A question for investors, however, is this: How will stocks react? Related: Everyone should keep an eye on this Persian Gulf island There are some unknowns. There's been no verification that Iran's nuclear enrichment facilities are, in fact, totally obliterated. It's not clear if Iran will try to cut a deal to stop the Israeli and U.S. bombing or opt somehow to play a long game of defending itself with missile shots at Israel and U.S. military bases in the Middle East. Nonetheless, there's a good chance Wall Street will seize on the attacks as a prime stock-buying opportunity. That's what happened in 2003's Second Gulf War when U.S.-led forces invaded Iraq and toppled the dictatorial regime of Saddam Hussein. Related: Tesla releases new details about its next big deal Stocks started to tumble in late January 2003 as another war against Iraq became inevitable. The Standard & Poor's 500 Index was down as much as 9% for the year on March 11. But then investors started to believe the invasion would go well, and the S&P 500 started to recover. Indeed, when Baghdad fell on April 9, 2003, the index had recovered all the early losses and was up 8.2% from the March low. And stocks never looked back. The S&P 500 finished up 26.4% in 2023. The gain from the March 2003 low to year-end: 38%. Mirrorpix/Getty Images One will be able to see how investors and markets are looking at the conflict starting at 6 p.m. ET Sunday. That's when futures trading in the S&P 500, the Dow Jones industrials and the Nasdaq-100 starts. Gains like 2003 might not happen. Iran was lobbing missiles at the Israeli cities of Tel Aviv and Haifa into Sunday. And, so far, there's no hint that Iran's leadership wants a cease fire. A prolonged fight might be bad for stocks. Iran has missiles and drones to deploy. It could block off Strait of Hormuz, through which 25% of the world's crude oil is shipped. Blocking the strait would send global oil prices sharply higher and cause havoc for the global economy. in fact, oil prices already have reacted. As tensions have grown between Israel and Iran (and now the United States), crude oil has climbed 29.3% to $73.84 per 42-gallon barrel from a May 5 closing low. U.S. gasoline prices have risen, too, about 4% or so, to about $3.20 a gallon, according to Related: Major analysts predict oil prices if Strait of Hormuz blocked Oil companies would profit. In fact, stocks in the S&P 500's Energy Sector are up 9.2% so far in June, the best performance by any of the 11 S&P 500 sectors. Oil-and-gas producer APA Corp. (APA) , the sector leader is up 15.8% over the last month, according to data. Exxon Mobil (XOM) has jumped 9.3%; Chevron (CVX) is has risen almost 9%. More Experts Analyst makes bold call on stocks, bonds, and goldTheStreet Stocks & Markets Podcast #8: Common Sense Investing With David MillerVeteran fund manager sends dire message on stocks Theoretically, the first-quarter earnings seasons is done, but some of the late stragglers due this week are important. These include: FedEx (FDX) , after Tuesday's close. FedEx shares have struggled, but there is hope. The delivery giant is doing business again with (AMZN) , and its business overall is growing again. But shares are off nearly 20% this year because of tariff worries. Earnings are estimated to rise 8.9% from a year ago to $5.89 a share. Revenue will be off slightly at $21.8 giant Carnival Corp. (CCL) , before Tuesday's open. Between August 2024 and Jan. 30, the shares doubled to $28.49 because bookings were beyond terrific. Then, the shares fell 49%, thanks to the Trump tariff plan and the mini-stock panic. Carnival is back to $23.77. The quarterly revenue estimate of $6.2 billion is up 7.3% from a year ago. Earnings of 24 cents a share would be up 118%.Chip maker Micron Technology (MU) shares are up 47% this year, and Wall Street likes - no, loves - the stock, whose chips have carved out a lucrative spot in artificial intelligence. In fact, the shares are already ahead of one analyst's one-year price target. The revenue estimate is $8.8 billion, up nearly 30% from a year ago. Earnings of $1.59 a share would be up 156%.Nike (NKE) is having a challenging year. The shares are down 21% this year, third-worst among the Dow Jones industrial stocks. True, it's selling athletic wear and shoes again on but it is extremely vulnerable to the Trump tariff hikes. Barrons says Nike's factories in Vietnam, Indonesia and China manufacture 50%, 27% and 18% of all its footwear. (Yes, that adds up to 95% of production.) The Nike revenue estimate: $10.7 billion, down 15.1% from a year ago. Earnings of 12 cents would be down 88%. Related: Veteran fund manager who predicted April rally updates S&P 500 forecast The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
